Fuertes, TeresaRamiro, Almudena RYébenesGarcía-Yébenes Mena, Virginia Pilar2024-01-082024-01-082020-10-03Fuertes T, Ramiro AR, de Yebenes VG. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends Immunol. 2020 Oct;41(10):932-947. doi: 10.1016/j.it.2020.08.006. Epub 2020 Sep 1. PMID: 328888201471-498110.1016/j.it.2020.08.006https://hdl.handle.net/20.500.14352/91808Non-Hodgkin lymphoma (NHL) is a diverse class of hematological cancers, many of which arise from germinal center (GC)-experienced B cells. Thus GCs, the sites of antibody affinity maturation triggered during immune responses, also provide an environment that facilitates B cell oncogenic transformation. miRNAs provide attractive and mechanistically different strategies to treat these malignancies based on their potential for simultaneous modulation of multiple targets. Here, we discuss the scientific rationale for miRNA-based therapeutics in B cell neoplasias and review recent advances that may help establish a basis for novel candidate miRNA-based therapies for B cell-NHL (B-NHL)engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://www.cell.com/trends/immunology/fulltext/S1471-4906(20)30183-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471490620301836%3Fshowall%3Dtruehttps://pubmed.ncbi.nlm.nih.gov/32888820/open access612.017LymphomaB lymphocyteMicroRNAsTherapyCiencias Biomédicas24 Ciencias de la Vida